

1 **Article title:** Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies
2 novel clusters and divergent ex-vivo drug responses

3

4 Jeppe F Severens^{1,2,3}, E Onur Karakaslar^{1,2,3}, Bert A van der Reijden⁴, Elena Sánchez-López^{3,5}, Redmar
5 R van den Berg⁶, Constantijn JM Halkes⁷, Peter van Balen⁷, Hendrik Veelken^{3,7}, Marcel JT Reinders^{1,2,3},
6 Marieke Griffioen⁷, Erik B van den Akker^{1,2,3}

7

8 ¹Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands

9 ²Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The Netherlands

10 ³Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, The Netherlands

11 ⁴Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center,
12 Nijmegen, The Netherlands

13 ⁵Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands

14 ⁶Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

15 ⁷Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

16

17 **Corresponding author:**

18 Erik B. van den Akker, PhD; Department of Biomedical Data Sciences, Leiden University Medical Center,
19 Leiden, The Netherlands; Eindhovenweg 20, 2333 ZC, Leiden, The Netherlands; Tel: +31 (0)71 526 85
20 57; Fax: +31 (0)71 526 82 80; E-mail: e.b.van_den_akker@lumc.nl

21

22 **Disclosure of interest**

23 The authors declare no competing financial interests.

24

25

26 **Abstract**

27 Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic abnormalities, but
28 recent literature indicates that transcriptomic phenotyping holds immense potential to further refine AML
29 classification. Here we integrated five AML transcriptomic datasets with corresponding genetic information to
30 provide an overview (n=1224) of the transcriptomic AML landscape. Consensus clustering identified 17 robust
31 patient clusters which improved identification of *CEBPA*-mutated patients with favourable outcomes, and
32 uncovered transcriptomic subtypes for *KMT2A* rearrangements (2), *NPM1* mutations (5), and AML with
33 myelodysplasia-related changes (AML-MRC) (5). Transcriptomic subtypes of *KMT2A*, *NPM1* and AML-MRC
34 showed distinct mutational profiles, cell type differentiation arrests and immune properties, suggesting
35 differences in underlying disease biology. Moreover, our transcriptomic clusters show differences in ex-vivo
36 drug responses, even when corrected for differentiation arrest and superiorly capture differences in drug
37 response compared to genetic classification. In conclusion, our findings underscore the importance of
38 transcriptomics in AML subtyping and offer a basis for future research and personalised treatment strategies.
39 Our transcriptomic compendium is publicly available and we supply an R package to project clusters to new
40 transcriptomic studies.

41 Introduction

42 In acute myeloid leukaemia (AML), recurrent genetic abnormalities (RGA) have been identified
43 through systematic genomic studies.¹⁻⁵ Based on these RGAs, the World Health Organization (WHO
44 2022) and International Consensus Classification (ICC 2022) define several AML subtypes, as well as a
45 heterogeneous subtype of AML with myelodysplasia-related changes (AML-MRC).^{6,7} RGAs are essential
46 for risk-stratification and are increasingly targeted with drugs.^{8,9}

47 AML subclassification is genetics-based, but transcriptomics holds immense potential to refine
48 AML classification further.^{1-3,10-12} Transcriptomic studies have led to the discovery of *CEBPA*-mutated
49 AML^{13,14}, and *NPM1*-mutated AML subtypes with different cell differentiation arrests and ex-vivo drug
50 responses.^{15,16} Similar stratification would be beneficial for AML-MRC, given its heterogeneity.^{17,18} Still, a
51 comprehensive examination of AML subtypes defined by gene expression has yet to be performed.
52 Furthermore, the differentiation arrest state is known to modify drug response in AML¹⁹, and failing to
53 account for this effect when comparing drug responses could skew conclusions.

54 Therefore, we integrated five mRNAseq datasets with corresponding genetic aberration data and
55 annotated cases according to WHO and ICC 2022 standards. We outline AML's transcriptomic landscape
56 and define transcriptional subtypes with distinct gene expressions, genetic aberrations, and cell type
57 arrests. We relate the clusters to ex-vivo drug responses independently of differentiation arrest and show
58 how they superiorly capture differences in response compared to genetic classification. We provide all
59 harmonised data and a transcriptional cluster predictor for future research. Our study underscores the
60 importance of incorporating transcriptomic data in AML classification.

61

62

63 **Methods**

64 **Transcriptomic data**

65 We acquired transcriptomics data of primary AML patients from blood or bone marrow from
66 BEAT^{3,20} (n = 425), TARGET² (n = 145), TCGA¹ (n = 150), and Leucegene^{11,21-23} (n = 399), and our in-
67 house LUMC²⁴ dataset (n = 95). Data statements and methods for transcriptome sequencing are
68 available in the referenced studies.

69 We acquired quantified gene expression for BEAT, TARGET and TCGA from
70 <https://portal.gdc.cancer.gov/> (release 36) and implemented the same pipeline for Leucegene and LUMC
71 to harmonise quantification. In short, FASTQ files were aligned and quantified with STAR²⁵ to the
72 GRCh38 reference genome²⁶, using Gencode v36²⁷ as the gene annotation index which included 60600
73 genes.

74 Gene expression count data were corrected with Combat-Seq²⁸ for the variables “cohort”, “sex”,
75 and “tissue”. We split Leucegene for the batch correction into Leucegene_stranded and
76 Leucegene_unstranded, since different sequencing libraries were used. We removed 8057 genes that
77 were not detected in all cohorts, leaving 52603 genes. Finally, we removed genes detected in less than
78 200 samples or with less than 300 counts leaving 41862 genes for our final dataset. We normalised the
79 corrected count data using the geometric mean and variance stabilising transformation (VST)²⁹ and
80 quantified the remaining cohort-specific variation using kBET.³⁰

81

82 **Genetic and patient data**

83 We acquired genetic data for the samples from the referenced studies in the form of mutation and
84 fusion calling, and cytogenetics data and clinical data on sex, age, blast percentage, and survival.
85 Blacklisted fusions as reported by Arriba³¹ were removed from the fusion calling data.

86 We harmonised the data by standardising the annotation of gene names, fusion genes, and
87 karyotyping. Using genetic data, we subclassified samples according to the WHO 2022⁶ and ICC 2022⁷.
88 Samples for which we found no RGA and all genetic data available were annotated as “No RGA found”.
89 We classified samples with missing data and “No RGA found” as “Inconclusive”.

90

91 **Clustering**

92 We employed consensus clustering^{32,33} on the batch-adjusted gene expression. First, we created
93 a weighted nearest neighbour graph³⁴ using the 2000 most variable genes (MVGs). MVGs were selected
94 via the median absolute deviation from samples with a blast percentage over 70% to minimise tumour
95 microenvironment effects. Using the Leiden algorithm³⁵ – with seed and resolution varied per iteration –
96 we generated 300 cluster assignments from the graph for each n_clusters ranging from 10 to 20, totaling
97 3300 assignments.

98 From these 3300 assignments we created a consensus matrix with values ranging between 0
99 and 1 based on pairwise co-clustering. We then converted this matrix into a distance matrix (1 -
100 consensus matrix) and conducted Ward.D2 hierarchical clustering. The final cluster count was
101 determined based on the individual separation of WHO classes and clusters displaying differential traits.

102

103 **Cluster stability**

104 To evaluate per sample clustering stability, we devised a stability score. We constructed a
105 consensus matrix for each n_clusters (300 assignments) and subtracted each co-clustering value from 1
106 if it was below 0.5. Then, we took the mean of all values per sample as the stability score, which ranged
107 from 0.5 to 1, with higher scores indicating less clustering ambiguity. To investigate correlation between
108 cluster stability and blast percentage we performed a Spearman correlation test. Additionally, we
109 generated tSNEs using 100 to 2500 MVGs to visually assess cluster stability.

110

111 **Cluster prediction**

112 To predict cluster assignments we trained a one-vs-rest SVM per cluster. As input we used the
113 uncorrected gene expression of the 2000 MVGs used for clustering. To select hyperparameters and
114 evaluate performance we utilised 5x5 nested cross-fold validation.

115 To improve predictions we included a reject option using a minimum distance to the decision
116 boundary. We determined this distance by looping over possible minimum values for the predictions of
117 the inner fold. We selected the minimum value with the highest Kappa for the accepted inner fold samples
118 and an accuracy < 0.5 for the rejected inner folds samples.

119 The final model was trained on the whole dataset, using 5-fold cross-validation to select
120 hyperparameters and the minimum decision boundary distance.

121 **Differential gene expression analysis**

122 Differential gene expression analysis between the clusters was performed using DESeq2²⁹ using
123 the corrected gene counts. We performed one-versus-rest analyses to identify differentially expressed
124 genes in one cluster compared to all others. We annotated genes as transcription factors or coding for
125 cell surface proteins using public databases.^{36,37}

126

127 **Aberration enrichment analysis**

128 To test if aberrations occurred more in a cluster than in others we first removed aberrations found
129 in only one cohort or which occurred in less than 1% of the samples. We also included high *MECOM*
130 expression in the analysis (VST expression > 6, based on the tail of a *MECOM* expression density plot).
131 We tested for enrichment per aberration by performing an one-sided Fisher exact test for one cluster
132 versus all others and adjusted p-values using the Benjamini-Hochberg (BH) procedure. We considered
133 aberrations with a false discovery ratio (FDR) < 0.05 enriched.

134

135 **Survival analysis**

136 We performed survival analysis using right censored overall survival data by generating Kaplan
137 Meier (KM) curves on BEAT and TCGA survival data, comparing different groups of patients with the log
138 rank test. We also performed Cox-regression using BEAT, TARGET and TCGA survival data for different
139 patient groups and included cohort, sex and age as co-variables to analyse hazard ratios.

140

141 **Expression based score**

142 We created cell type score to assess the differentiation arrest of AML samples, using the mean
143 expression of 30 marker genes for six haematological cells.³⁸ Additionally, we created immune phenotype
144 scores for cytolytic infiltration and HLA I and HLA II antigen presenting cells using the mean expression
145 of marker genes.³⁹

146

147 **Drug response analysis**

148 To analyse drug response differences, we used ex-vivo drug response data of 331 BEAT³
149 samples, quantified as area under the curve (AUC). We excluded drugs with less than 200 samples or
150 missing data for any cluster, leaving 103 of the 123 drugs. We used a Kruskal-Wallis test for each drug
151 with the AUC as response and clusters as groups to compare the average drug response per cluster.

152 Drugs with a significant difference (FDR<.05) were analysed with one-sided Wilcoxon tests to identify
153 clusters with low AUCs. Additionally, we performed a Kruskal-Wallis test for each drug with the ICC 2022
154 diagnosis as groups, to compare with clusters as groups.

155 Multivariate linear models (LM) were evaluated per drug to test if clusters were sensitive to a drug
156 when adjusted for cell type, with AUC as response and cluster membership (one-versus-rest) and the six
157 cell type scores as explaining variables. Similarly, we fitted LMs but with cluster membership and ICC
158 2022 diagnoses as variables. We considered clusters sensitive to a drug if the cluster membership's FDR
159 was below 0.05 and the LM coefficient was negative. All p-values were corrected using BH.

160

161 **Data Sharing Statement**

162 The datasets generated and/or analysed during the current study are available from
163 www.github.com/jeppeseverens/AMLmap.

164

165 **Code availability**

166 All code used to generate results is available on reasonable request. The predictor is available from
167 www.github.com/jeppeseverens/AMLmapR as an R package.

168

169 **Results**

170 **Multi-cohort AML gene expression compendium**

171 We collected 1224 RNAseq samples from adult (BEAT, TARGET, TCGA, Leucegene, LUMC)
172 and paediatric (TARGET) cohorts with corresponding genetic and clinical data (**Figure 1A**). We quantified
173 gene expression with the same pipeline and corrected counts for cohort, sex and source tissue
174 (**Supplemental Figure 1**). Sample classification by their genetic data according to the WHO (**Figure 1C**)
175 and ICC was successful for 97% of the samples. In line with previous reports, frequencies of the AML
176 subtypes were similar for the adult cohorts but different between paediatric and adult cohorts
177 (**Supplemental Table 1**), confirming that our dataset is representative of the AML landscape.^{40,5}

178 **Transcriptomics define 17 AML clusters**

179 Next, we assigned AML cases to 17 transcriptional clusters using consensus clustering (**Figure**
180 **Supplemental Figures 2 & 3**). We named the clusters based on genetic diagnoses (**Figure 1B**,
181 **Supplemental Figure 4 & 5**). As expected, the distribution over the clusters was different for paediatric

182 and adult cohorts, exemplified by the large percentage of paediatric samples in the $KMT2A^T$ clusters
183 (26%), and adult samples in the $NPM1^T$ (93%) and $AML-MRC^T$ (94%) clusters (**Supplemental Table 1**,
184 **Supplemental Figure 6**). However, samples of identical AML genetic subtypes from adult and paediatric
185 cohorts clustered together, indicating that the 17 clusters capture differences in AML biology.

186 We examined clustering robustness using the stability score (**Supplemental Figure 7**). Median
187 clustering stability was high (0.97-1.00), with $AML-MRC(3)^T$ showing the lowest stability. A correlation
188 test revealed a significant but weak correlation ($\rho = 0.18$, $p\text{-value} < .001$) between blast percentage and
189 clustering robustness, but blast percentage varied greatly in clusters. tSNEs generated using different
190 MVGs (**Supplemental Figure 8**) were stable from 500 to 2500 features. These results show that
191 clustering was robust and only weakly influenced by blast percentage.

192 We developed a transcriptional cluster predictor using uncorrected counts as input (accuracy =
193 0.90), demonstrating the persistence of expression patterns. The quality of the predictor was further
194 improved (accuracy = 0.95) by including a reject option (10% rejected) (**Supplemental Figure 9**).

195 Next, we tested for enrichment of mutations, fusions and cytogenetic aberrations ($n=102$) (**Figure**
196 **1E**, p -values and frequencies in **Supplemental Table 2**). Four transcriptomic clusters corresponded to
197 singular genetic AML subtypes: $RUNX1::RUNX1T1^T$ ($RUNX1::RUNX1T1$: 94%, $FDR < .001$),
198 $CBFB::MYH11^T$ ($CBFB::MYH11$: 95%, $FDR < .001$), $PML::RARA^T$ ($PML::RARA$: 100%, $FDR < .001$), and
199 $NUP98^T$ ($NUP98::NSD1$: 45%, $FDR < .001$). Risk-stratification for survival based on transcriptional
200 subtypes performed similarly to genetics (**Supplemental Figure 10 & 11**). We identified no enrichment
201 for $BCR::ABL1$ and $DEK::NUP214$, possibly due to their limited occurrence. For $KMT2A$ rearrangements,
202 $CEBPA$ mutations, $NPM1$ mutations, and $AML-MRC$, we found evidence that transcriptomics can refine
203 subtyping, as described below.

204

205 Transcriptome analysis identifies two $KMT2A$ -related clusters

206 The WHO classification defines a single $KMT2A$ -rearranged subtype ($KMT2A-r$), while the ICC
207 recognises $KMT2A::MLLT3$ and other $KMT2A$ fusions as distinct.^{6,7} We identified two $KMT2A$ fusion
208 clusters. $KMT2A(1)^T$ was significantly enriched for $KMT2A::MLLT3$ (31%, $FDR < .001$), $KMT2A::MLLT10$
209 (19%, $FDR < .001$) and any $KMT2A$ fusion (67%, $FDR < .001$), while $KMT2A(2)^T$ was enriched for
210 $KMT2A::MLLT4$ (67%, $FDR < .001$) and high $MECOM$ expression (80%, $FDR < .001$) (**Figures 2A & B**).

211 Interestingly, we found cases with *NPM1* mutations and trisomy 8/8q localised in *KMT2A(1)*^T, indicating
212 that these lead to *KMT2A* fusion-like gene expression.

213 The genes *LAMP5*, and *ADCY9* showed high expression in *KMT2A(1)*^T and low expression in
214 *KMT2A(2)*^T (**Figure 2B**), and all have been shown to contribute to AML pathogenesis^{41,42}. Additionally,
215 the transcription factor (TF) *ETV2* was highly expressed in *KMT2A(1)*^T, while the TF *ERG* displayed high
216 expression in *KMT2A(2)*^T. The cell type scores revealed *KMT2A(1)*^T to have a significantly higher
217 promonocyte-like score (FDR<.001), while *KMT2A(2)*^T was more hematopoietic stem cell (HSC)-like
218 (FDR<.001) (**Figure 2B, Supplemental Figure 12**). FAB annotations showed similar results for
219 *KMT2A(1)*^T, which had a high M5 (monocytic leukaemia) fraction (90%), while *KMT2A(2)*^T was more
220 mixed (**Figure 2C**). Overall, we found that gene expression-based separation of *KMT2A*-r did not align
221 with the ICC 2022 classification.

222

223 **The *CEBPA*^T cluster indicates a favourable prognosis**

224 As acknowledged in the ELN2022, patients with a *CEBPA* bZIP inframe mutation have a
225 favourable prognosis.^{8,43} We identified a transcriptional *CEBPA*^T cluster significantly enriched for mutated
226 *CEBPA* cases (72%, FDR<.001), with 42% of the samples having a *CEBPA* bZIP indel, either as single
227 mutation or combined with an N-terminal frameshift mutation (**Figure 3A & B**). The remaining samples
228 contained other mutations in the bZIP area or N-terminal region or had no detectable *CEBPA* mutation.
229 Of note, a single *CEBPA* bZIP indel case resided outside the *CEBPA*^T cluster. This patient had an *IDH*-
230 R132 mutation with a VAF=0.47, while the *CEBPA* bZIP in-frame mutation had a VAF=0.21. This finding
231 suggests that the *IDH*-R132 mutation dominates the expression pattern, placing this case in cluster AML-
232 *MRC(1)*^T. Conversely, all *CEBPA*^T cluster patients showed similar favourable outcomes (log-rank test: p-
233 value=.80), irrespective of whether the *CEBPA* bZIP inframe mutation was detected (**Figure 3C**). The
234 *CEBPA*^T cluster thus marks patients with a favourable outcome regardless of *CEBPA* mutation detection,
235 which the *CEBPA*^T expression profile can detect.

236 **Gene expression profiling identifies five transcriptional *NPM1*-related clusters**

237 The 2022 WHO and ICC classifications include one subtype of *NPM1*-mutated AML.^{6,7} However,
238 we identified five clusters enriched for mutated *NPM1* (**Figure 4**). We observed elevated expression of
239 *HOXA3*, *HOXB5*, and *MEIS1* (**Figure 4A**), which has been earlier associated with *NPM1* mutations.⁴⁴

240 Interestingly, *NPM1* mutation-lacking samples generally also exhibited high expression of these genes,
241 suggesting that there are alternative mishaps that disrupt these genes leading to *NPM1* mutated-like
242 AML.

243 *NPM1(1)^T* exhibited the highest percentage (95%, FDR<.001) of *NPM1* mutated samples and
244 was significantly enriched for *IDH1*-R132 (25%, FDR<.001), *IDH2*-R140 (37%, FDR<.001), and *TET2*
245 (33%, FDR<.001) co-mutations (**Figure 4A**). *NPM1(2)^T* samples were enriched for *FLT3*-ITD mutations
246 (84%, FDR<.001), but *FLT3*-ITD was also enriched in *NPM1(1)^T*, *NPM1(3)^T* and *NPM1(4)^T* (42-43%, all
247 FDR<.001). Additionally, *NPM1(4)^T* and *NPM1(5)^T* had a significantly lower variant allele frequency for
248 mutated *NPM1* (**Figure 4B**). We found two *NPM1::MLF1* cases in our compendium, which both clustered
249 in *NPM1(3)^T*. *NPM1::MLF1* has been shown to localise in the cytoplasm⁴⁵, like mutated *NPM1*, possibly
250 leading to a similar expression profile as *NPM1*-mutated cases.

251 Each of the *NPM1*-related clusters exhibited unique marker genes (**Figure 4A**). For instance,
252 *FTO* expression was high in *NPM1(1)^T*. Additionally, *LYRM1*, *ADAM8*, and *DNAJC13* were elevated in
253 *NPM1(2)^T*, *NPM1(4)^T*, and *NPM1(5)^T*, respectively. *NPM1(3)^T* had a less distinct expression pattern,
254 suggesting a more heterogeneous cluster. Also, we observed differential expression of TFs (*RUNX1*,
255 *PRDM16*, *SPI1*)^{46,47} – even in samples lacking the *NPM1* mutation – and TF expression aligned with cell
256 differentiation stages.

257 *NPM1(1)^T* and *NPM1(2)^T* displayed a HSC-like expression pattern, *NPM1(3)^T* was mixed,
258 whereas *NPM1(4)^T* and *NPM1(5)^T* were more differentiated (**Figure 4A, Supplemental Figure 12**). FAB
259 annotations showed additional differences, with *NPM1(5)^T* containing fewer M4 (myelomonocytic
260 leukaemia) but more M5 (monocytic leukaemia) cases than *NPM1(4)^T* (**Figure 4C & D**). Using scores for
261 HLA I and HLA II antigen-presenting cells³⁹ we found *NPM1(1)^T* to have significantly lower HLA I
262 (FDR<.001) and HLA II (FDR<.001) scores than the other clusters (**Figure 4E & F**). *NPM1(1)^T* and
263 *NPM1(5)^T* patients were significantly older (FDR<.05), while *NPM1(3)^T* patients were younger (FDR<.01)
264 (**Supplemental Figure 6F**). Our findings emphasise the existence of distinct *NPM1*-related subsets,
265 highlighting the limitations of relying solely on genetic classification.

266 **Gene expression profiling identifies five transcriptional AML-MRC-related clusters**

267 The ICC 2022 divides AML-MRC into three groups based on TP53 mutations, myelodysplasia-
268 related gene mutations, and cytogenetic abnormalities.⁷ Our study identified five gene expression-based

269 AML-MRC related clusters (**Figure 5**), with varying fractions of *TP53* mutations, MRC gene mutations,
270 and cytogenetic abnormalities.

271 Despite sharing these mishaps, each cluster had unique characteristics (**Figure 5A**). AML-
272 MRC(1)^T was characterised by *IDH1-R132* (49%, FDR<.001) and *IDH2-R170* (27%, FDR<.001)
273 mutations. A *DNMT3A* and *IDH1/2* mutated subtype has been reported⁵, but 41% of the AML-MRC(1)^T
274 cases lacked *DNMT3A* mutations. AML-MRC(2)^T, AML-MRC(3)^T, and AML-MRC(4)^T were all enriched
275 (FDR<.001) for *TP53* mutations, cytogenetic abnormalities and high *MECOM* expression, and AML-
276 MRC(3)^T also contained a large fraction of mutated MRC genes (65%, FDR<0.001). AML-MRC(5)^T stood
277 out with the highest fraction of mutated MRC genes cases (81%, FDR<.001) and the lowest fraction of
278 *TP53* mutations (6%) and cytogenetic abnormalities (34%).

279 We found marker genes for all clusters (**Figure 5A**). For instance, high *SRSF12* marked AML-
280 MRC(1)^T, and *LINC00865* marked AML-MRC(5)^T. AML-MRC(2)^T presented high glycoporphin genes and
281 *UROD* expression, suggesting an association with acute erythroid leukaemia.^{48–50} Distinct cell
282 differentiation scores further highlighted differences (**Figure 5A-C, Supplemental Figure 12**). For
283 example, AML-MRC(1)^T showed high progenitor-like scores, with 65% M1 (minimal maturation) cases,
284 and AML-MRC(3)^T showed a more differentiated pattern, with 54% M2 (significant maturation) cases.
285 AML-MRC(2)^T was the only cluster with M6 (erythroid leukaemia) – in line with high expression of
286 erythrocyte cell markers – and M7 (megakaryocytic leukaemia) cases. Additionally, high cytolytic cell
287 infiltration has been reported for AML-MRC cases.³⁹ Using the same score (**Figure 5D**) we found that the
288 cytolytic infiltration was significantly (FDR<.05) lower for AML-MRC(1)^T and higher for AML-MRC(2)^T
289 compared to the other AML-MRC clusters. Our results demonstrate that different AML-MRC
290 transcriptomic clusters can be identified, showing genetic enrichments that do not necessarily align with
291 the ICC 2022 classification.

292 **AML clusters exhibit cell type-independent differences in ex-vivo drug responses**

293 Finally, we assessed the drug sensitivity of the transcriptional AML subtypes. Using ex-vivo drug
294 response data, we discovered 101 drug-cluster combinations with significantly lower resistance
295 (FDR<.05), of which 21 combinations remained statistically significant (FDR<.05) when adjusting for cell
296 differentiation status (**Figure 6, Supplemental Figure 13, Supplemental Table 3**).

297 The ex-vivo drug responses between *NPM1*-related clusters were often divergent, exemplified by
298 venetoclax and selumetinib (**Figure 6A,B**). *NPM1(1)^T*, *NPM1(2)^T* and *NPM1(3)^T* mostly responded
299 positively to tyrosine kinase inhibitors and CDK kinase inhibitors. *NPM1(4)^T* and *NPM1(5)^T* samples were
300 more sensitive to PI3K and MAPK kinase inhibitors. We also found drugs where only one cluster was
301 responsive, exemplified by axitinib for *NPM1(4)^T* where this effect remained significant (FDR<.05) when
302 controlled for cell type scores (**Figure 6C**).

303 Several drugs demonstrated favourable ex-vivo responses in *KMT2A(1)^T* compared to the other
304 clusters, exemplified by idelalisib. For *KMT2A(2)^T* we found no significant responsive drugs, but testing
305 was limited due to small cluster size. For the AML-MRC clusters, most drugs showed strong resistance.
306 Still, specific drugs were more effective for *AML-MRC(1)^T*, *AML-MRC(4)^T*, and *AML-MRC(5)^T* (**Figure 6A,**
307 **B**), suggesting potential for targeted treatments in this diverse, high-risk patient group.

308 Next, we examined if transcriptional clusters provide insights beyond genetic classifications.
309 Comparing the AUCs of each drug between groups, we found 71 drugs with significantly different
310 (FDR<.05) median AUCs between the clusters, while only 21 drugs were significantly different between
311 ICC 2022 classes (**Figure 6D**). Additionally, 57 of the 101 cluster-drug combinations remained significant
312 (FDR<.05) when cluster membership and ICC 2022 diagnosis were included in a LM, suggesting that the
313 transcriptional clusters offer information beyond genetic classification.

314 Overall, our findings offer novel opportunities for targeted therapy in AML. We observed effective
315 drug responses even after adjusting for differentiation status, possibly allowing gene expression-based
316 subtypes to guide treatment strategies.

317 **Discussion**

318 This study presents an overview of transcriptomics in AML and provides a framework for
319 transcriptional subtyping. We integrate multiple cohorts to identify 17 robust transcriptional subtypes that
320 subclassify ~75% of our datasets' patients. We make the harmonised data and a cluster predictor publicly
321 available, facilitating future research.

322 For the *CEBPA^T* cluster, we show that patients without a detected *CEBPA* bZIP indel mutation
323 still have similar favourable survival. Patients without the canonical *CEBPA* mutation in the *CEBPA^T*
324 cluster could be explained by undetected mutations, given the complexities of *CEBPA* sequencing. Also,

325 *CEBPA* hypermethylation has been described to lead to a similar expression profile.⁵¹ The use of the
326 *CEBPA*^T gene signature for risk stratification could be a relevant alternative to detect these favourable-
327 outcome patients.

328 *KMT2A(1)*^T mainly featured *KMT2A* with the fusion partners *MLLT3*, *MLLT10* and *MLLT1* – all
329 TFs in the super elongation complex whose perturbation leads to disrupted hematopoietic lineage
330 commitment.⁵² In contrast, *KMT2A(2)*^T featured *KMT2A::MLLT4*, which is thought to cause leukaemia by
331 promoting self-association⁵³. Interestingly, *MLLT3*, *MLLT10* and *MLLT1* all fuse a specific region of
332 *KMT2A*, but *MLLT4* shows less specificity.⁵⁴ Collectively, these results suggest that two types of
333 oncogenic mechanisms involving *KMT2A* fusions exist that may be marked with unique gene expression
334 patterns.

335 We identified five *NPM1*-related clusters, further underpinning findings of transcriptional
336 heterogeneity among *NPM1*-mutated patients^{15,16,55}, but also providing additional insight into co-
337 mutations and detailed subtypes. We observed several samples from *NPM1*-related clusters that lacked
338 the *NPM1* mutation. Several rare *NPM1* fusions, like *NPM1::MLF1*, have been described to lead to
339 cytoplasmic localisation of *NPM1*, comparable to the canonical *NPM1* frameshift.^{45,56} These non-
340 canonical mishaps could lead to a *NPM1*-mutated-like presentation and similarities in survival and drug
341 response should be explored. Additionally, *NPM1(1)*^T was mutually exclusive enriched for *IDH1/2* and
342 *TET2* co-mutations. *IDH1/2* mutations lead to an aberrant alpha-ketoglutarate metabolism and are
343 functionally complementary to *TET2* loss-of-function mutations⁵⁷. While *NPM1(1)*^T and *NPM1(5)*^T show
344 significant enrichments for *TET2*, only *NPM1(1)*^T shows this mutual exclusivity with *IDH1/2*. This suggests
345 that only *NPM1(1)*^T is driven by aberrant alpha-ketoglutarate metabolism, which should be further studied
346 using metabolomics.

347 Similarly, cytogenetic abnormalities, AML-MRC mutations and high *MECOM* expression were
348 found in all AML-MRC clusters, but lead to different gene expression. A possible explanation could be
349 clonal architecture and the differentiation state of the cell acquiring the leukemic aberration, both known
350 to influence the biology of the resultant leukaemia.^{58,59} To our knowledge, we are the first to show different
351 gene expression-based subgroups in AML-MRC, with divergent drug responses. Accurate identification
352 of these clusters requires gene expression analysis, showing the relevance of our work.

353 We found no additional survival differences between other clusters. However, data availability
354 limited the survival analysis, and different treatment protocols across studies could have led to

355 confoundment. Survival differences between transcriptional subtypes should thus be further explored in
356 one large cohort. However, we did find marked differences in drug responses between the clusters.
357 Ideally, new studies should test in-patient efficacy of drugs with good ex-vivo responses in transcriptional
358 subtypes. Furthermore, transcriptional subtyping could aid AML specialists in the highly complex field of
359 clinical care and lead to multidisciplinary tailored-based treatment advice.⁶⁰

360 In conclusion, the transcriptional subtypes reveal heterogeneity in AML not captured by genetic
361 classification. Integration of transcriptomics into AML research and diagnostics could improve disease
362 understanding and lead to more treatment options.

363

364 **Acknowledgements**

365 This project was funded by a strategic investment of the Leiden University Medical Center, embedded
366 within the Leiden Oncology Center, and executed within the Leiden Center for Computational Oncology.
367 EvdA was funded by a personal grant from the Dutch Research Council (NWO; VENI: 09150161810095).
368 The funding bodies had no role in the study design, the collection, analysis, and interpretation of data,
369 the writing of the manuscript, and the decision to submit the manuscript for publication.

370

371 **Author Contributions**

372 M.J.R., M.G., and E.B.A. conceived and designed the project; E.B.A. acquired funding; E.B.A. performed
373 project administration; M.G., E.B.A., H.V., R.R.B., C.J.M.H., P.B. performed oversight and management
374 of resources (data generation, collection, transfer, infrastructure, data processing); J.F.S. performed
375 computational and statistical analyses; J.F.S., E.B.A., M.G., E.O.K., E.S.-L. performed analyses and
376 interpretation; J.F.S. performed and structured data visualisation; M.J.R., M.G. and E.B.A. provided
377 supervision and scientific direction; J.F.S. wrote the manuscript; and all authors critically reviewed the
378 manuscript and figures.

379

380 **Disclosure of interest**

381 The authors declare no competing financial interests.

382

383 **References**

384 1. The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De

- 385 Novo Acute Myeloid Leukemia. *N. Engl. J. Med.* 2013;368(22):2059–2074.
- 386 2. Farrar JE, Schuback HL, Ries RE, et al. Genomic Profiling of Pediatric Acute Myeloid Leukemia
387 Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. *Cancer Res.*
388 2016;76(8):2197–2205.
- 389 3. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid
390 leukaemia. *Nat.* 2018 5627728. 2018;562(7728):526–531.
- 391 4. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute
392 Myeloid Leukemia. *N. Engl. J. Med.* 2016;374(23):2209–2209.
- 393 5. Tazi Y, Arango-Ossa JE, Zhou Y, et al. Unified classification and risk-stratification in Acute Myeloid
394 Leukemia. *Nat. Commun.* 2022;13(1):4622.
- 395 6. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification
396 of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia.*
397 2022;36(7):1703–1719.
- 398 7. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid
399 Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood.*
400 2022;140(11):1200–1228.
- 401 8. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022
402 recommendations from an international expert panel on behalf of the ELN. *Blood.*
403 2022;140(12):1345–1377.
- 404 9. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia
405 using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master
406 Trial. *Nat. Med.* 2020;26(12):1852–1858.
- 407 10. Valk PJM, Verhaak RGW, Beijen MA, et al. Prognostically Useful Gene-Expression Profiles in
408 Acute Myeloid Leukemia. *N. Engl. J. Med.* 2004;350(16):1617–1628.
- 409 11. Lavallée V-P, Baccelli I, Kros J, et al. The transcriptomic landscape and directed chemical
410 interrogation of MLL-rearranged acute myeloid leukemias. *Nat. Genet.* 2015;47(9):1030–1037.
- 411 12. Mou T, Pawitan Y, Stahl M, et al. The transcriptome-wide landscape of molecular subtype-specific
412 mRNA expression profiles in acute myeloid leukemia. *Am. J. Hematol.* 2021;96(5):580–588.
- 413 13. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al. Double CEBPA mutations, but not
414 single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene
415 expression profile that is uniquely associated with a favorable outcome. *Blood.* 2009;113(13):3088–
416 3091.
- 417 14. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and
418 gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal
419 AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
420 *Blood.* 2011;117(8):2469–2475.
- 421 15. Mer AS, Heath EM, Madani Tonekaboni SA, et al. Biological and therapeutic implications of a
422 unique subtype of NPM1 mutated AML. *Nat. Commun.* 2021;12(1):1054.
- 423 16. Cheng W-Y, Li J-F, Zhu Y-M, et al. Transcriptome-based molecular subtypes and differentiation
424 hierarchies improve the classification framework of acute myeloid leukemia. *Proc. Natl. Acad. Sci.*

- 425 2022;119(49):e2211429119.
- 426 17. de Leeuw DC, Ossenkoppele GJ, Janssen JJWM. Older Patients with Acute Myeloid Leukemia
427 Deserve Individualized Treatment. *Curr. Oncol. Rep.* 2022;24(11):1387–1400.
- 428 18. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in
429 the Netherlands: a long haul is needed to change nothing into something | Leukemia.
- 430 19. Zeng AGX, Bansal S, Jin L, et al. A cellular hierarchy framework for understanding heterogeneity
431 and predicting drug response in acute myeloid leukemia. *Nat. Med.* 2022;28(6):1212–1223.
- 432 20. Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in
433 acute myeloid leukemia. *Cancer Cell.* 2022;40(8):850-864.e9.
- 434 21. Macrae T, Sargeant T, Lemieux S, et al. RNA-Seq reveals spliceosome and proteasome genes as
435 most consistent transcripts in human cancer cells. *PLoS One.* 2013;8(9):e72884.
- 436 22. Lavallée V-P, Lemieux S, Boucher G, et al. RNA-sequencing analysis of core binding factor AML
437 identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. *Blood.*
438 2016;127(20):2498–2501.
- 439 23. Pabst C, Bergeron A, Lavallée V-P, et al. GPR56 identifies primary human acute myeloid leukemia
440 cells with high repopulating potential in vivo. *Blood.* 2016;127(16):2018–2027.
- 441 24. Arindrarto W, Borràs DM, de Groen RAL, et al. Comprehensive diagnostics of acute myeloid
442 leukemia by whole transcriptome RNA sequencing. *Leuk. 2020 351.* 2020;35(1):47–61.
- 443 25. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinforma.*
444 *Oxf. Engl.* 2013;29(1):15–21.
- 445 26. Genome Reference Consortium.
- 446 27. Frankish A, Diekhans M, Jungreis I, et al. GENCODE 2021. *Nucleic Acids Res.* 2021;49(D1):D916–
447 D923.
- 448 28. Zhang Y, Parmigiani G, Johnson WE. ComBat-seq: batch effect adjustment for RNA-seq count
449 data. *NAR Genomics Bioinforma.* 2020;2(3):lqaa078.
- 450 29. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
451 data with DESeq2. *Genome Biol.* 2014;15(12):550.
- 452 30. Büttner M, Miao Z, Wolf FA, Teichmann SA, Theis FJ. A test metric for assessing single-cell RNA-
453 seq batch correction. *Nat. Methods.* 2019;16(1):43–49.
- 454 31. Uhrig S, Ellermann J, Walther T, et al. Accurate and efficient detection of gene fusions from RNA
455 sequencing data. *Genome Res.* 2021;31(3):448–460.
- 456 32. Monti S, Tamayo P, Mesirov J, Golub T. Consensus Clustering: A Resampling-Based Method for
457 Class Discovery and Visualization of Gene Expression Microarray Data. *Mach. Learn.*
458 2003;52(1):91–118.
- 459 33. Jeub LGS, Sporns O, Fortunato S. Multiresolution Consensus Clustering in Networks. *Sci. Rep.*
460 2018;8(1):3259.
- 461 34. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for
462 Dimension Reduction. 2020;
- 463 35. Traag VA, Waltman L, van Eck NJ. From Louvain to Leiden: guaranteeing well-connected
464 communities. *Sci. Rep.* 2019;9(1):5233.

- 465 36. Lambert SA, Jolma A, Campitelli LF, et al. The Human Transcription Factors. *Cell*.
466 2018;172(4):650–665.
- 467 37. Bausch-Fluck D, Hofmann A, Bock T, et al. A Mass Spectrometric-Derived Cell Surface Protein
468 Atlas. *PLOS ONE*. 2015;10(4):e0121314.
- 469 38. van Galen P, Hovestadt V, Wadsworth II MH, et al. Single-Cell RNA-Seq Reveals AML Hierarchies
470 Relevant to Disease Progression and Immunity. *Cell*. 2019;176(6):1265-1281.e24.
- 471 39. Dufva O, Pölönen P, Brück O, et al. Immunogenomic Landscape of Hematological Malignancies.
472 *Cancer Cell*. 2020;38(3):380-399.e13.
- 473 40. Patel JP, Gönen M, Figueroa ME, et al. Prognostic Relevance of Integrated Genetic Profiling in
474 Acute Myeloid Leukemia. *N. Engl. J. Med*. 2012;366(12):1079–1089.
- 475 41. Gracia-Maldonado G, Clark J, Mulloy JC, Kumar AR. LAMP5 - a Novel Target of MLL-Fusion
476 Proteins Is Required for the Propagation of Leukemia. *Blood*. 2016;128(22):1512.
- 477 42. Milan T, Celton M, Lagacé K, et al. Epigenetic changes in human model KMT2A leukemias
478 highlight early events during leukemogenesis. *Haematologica*. 2022;107(1):86–99.
- 479 43. Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute
480 myeloid leukemia. *Blood Adv*. 2022;6(1):238–247.
- 481 44. Brunetti L, Gundry MC, Sorcini D, et al. Mutant NPM1 maintains the leukemic state through HOX
482 expression. *Cancer Cell*. 2018;34(3):499-512.e9.
- 483 45. Falini B, Bigerna B, Pucciarini A, et al. Aberrant subcellular expression of nucleophosmin and NPM-
484 MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML.
485 *Leukemia*. 2006;20(2):368–371.
- 486 46. Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of hematopoietic stem cells.
487 *Blood*. 2011;117(19):5057.
- 488 47. Imperato MR, Cauchy P, Obier N, Bonifer C. The RUNX1–PU.1 axis in the control of
489 hematopoiesis. *Int. J. Hematol*. 2015;101(4):319–329.
- 490 48. Hollox EJ, Louzada S. Genetic variation of glycophorins and infectious disease. *Immunogenetics*.
491 2022;
- 492 49. Greaves MF, Sieff C, Edwards PAW. Monoclonal Antiglycophorin as a Probe for Erythroleukemias.
493 *Blood*. 1983;61(4):645–651.
- 494 50. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human
495 leukaemia cell line K562. *Nature*. 1979;278(5702):364–365.
- 496 51. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, et al. Characterization of
497 CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
498 *Haematologica*. 2011;96(3):384–392.
- 499 52. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-
500 based leukaemogenesis. *Nat. Rev. Cancer*. 2010;10(10):721–728.
- 501 53. Liedtke M, Ayton PM, Somerville TCP, Smith KS, Cleary ML. Self-association mediated by the
502 Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. *Blood*.
503 2010;116(1):63–70.
- 504 54. Meyer C, Larghero P, Almeida Lopes B, et al. The KMT2A recombinome of acute leukemias in

- 505 2023. *Leukemia*. 2023;37(5):988–1005.
- 506 55. Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. A distinct immunophenotype
507 identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
508 *Am. J. Hematol.* 2018;93(4):504–510.
- 509 56. Martelli MP, Rossi R, Venanzi A, et al. Novel NPM1 exon 5 mutations and gene fusions leading to
510 aberrant cytoplasmic nucleophosmin in AML. *Blood*. 2021;138(25):2696–2701.
- 511 57. Figueroa ME, Wahab OA, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a
512 hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
513 *Cancer Cell*. 2010;18(6):553–567.
- 514 58. Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-
515 throughput single-cell genomics. *Nat. Commun.* 2020;11(1):5327.
- 516 59. Krivtsov AV, Figueroa ME, Sinha AU, et al. Cell of origin determines clinically relevant subtypes of
517 MLL-rearranged AML. *Leukemia*. 2013;27(4):852–860.
- 518 60. Willemsen AECAB, Krausz S, Ligtenberg MJL, et al. Molecular tumour boards and molecular
519 diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
520 *Br. J. Cancer*. 2019;121(1):34–36.

521 **Figure legends**

522 **Figure 1: Transcriptomic analysis further stratifies AML.**

523 **A)** Flowchart of the used data and methods. **B)** Sankey plot showing the assignment of WHO 2022
524 diagnoses over the identified clusters. **C)** tSNE visualisation of the gene expression of patient samples.
525 Each dot represents a patient. The samples are coloured according to the WHO 2022 subtyping of AML.
526 **D)** The same tSNE visualisation as in **C**, but samples are coloured according to the 17 clusters. **E)** Dot
527 plots that show enriched aberrations in the 17 clusters. The dots are coloured according to the adjusted
528 p-value. The dots are sized according to the sample fraction with the aberration in the cluster. The x-axis
529 shows the aberrations, and the y-axis shows the clusters. We only visualised enriched aberrations that
530 occurred in at least 10% of the patients in a cluster.

531

532 **Figure 2: Transcriptome analysis identifies two *KMT2A*-related clusters.**

533 **A)** tSNE visualisation of patient samples, coloured according to *KMT2A*-fusion or *NPM1* mutation and
534 trisomy 8. **B)** Waterfall plot of aberrations in the *KMT2A* clusters, including the percentage of samples
535 with the aberration. The plot is combined with heatmaps showing the expression of marker genes and
536 cell type scores. The columns are samples, which are split according to transcriptional clusters. **C)**
537 Fraction of FAB annotations per cluster. HSC = hematopoietic stem cells, Prog. = progenitor, GMP =
538 granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC = conventional
539 dendritic cells

540

541 **Figure 3: The *CEBPA*^T cluster indicates a favourable prognosis.**

542 **A)** Waterfall plot and gene expression heatmap of all samples in the *CEBPA*^T cluster and samples with a
543 *CEBPA* mutation located outside the *CEBPA*^T cluster. **B)** tSNE visualisation of patient samples, coloured
544 according to the type of *CEBPA* mutation. For samples with multiple *CEBPA* mutations, we used the
545 ordering as in **A** to decide which mutation to display. **C)** Kaplan-Meier curve of the survival of BEAT and
546 TCGA patients in and outside the *CEBPA*^T cluster.

547

548 **Figure 4: Gene expression profiling identifies five transcriptional *NPM1*-related clusters.**

549 **A)** Waterfall plot of aberrations in the *NPM1*-related clusters, including the percentage of samples with
550 the aberration. The plot is combined with heatmaps showing the expression of marker genes and cell

551 type scores. The columns are samples, which are split according to transcriptional clusters. **B)** Boxplot
552 showing the scaled variant allele frequency (VAF) of mutated *NPM1* from the BEAT, Leucegene, and
553 LUMC cohorts. The VAF was scaled per gene and study to allow for a combined analysis. We used a
554 two-sided Wilcoxon test to test for statistical differences and Benjamini-Hochberg to adjust p-values for
555 multiple testing. **C)** tSNE visualisation of patient samples, coloured according to the FAB annotation. Only
556 *NPM1*-related clusters are coloured; the rest are in grey. **D)** Fraction of FAB annotations per cluster. **E)**
557 and **F)** show boxplots of HLA I and HLA II antigen presenting cell scores, respectively. Tests were
558 performed as in **B)**, but were only done between the two *KMT2A*^T, the five *NPM1*^T and the five *AML-MRC*^T
559 clusters. FDR values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001. HSC = hematopoietic stem cells, Prog.
560 = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC
561 = conventional dendritic cells, VAF = variant allele frequency

562

563 **Figure 5: Gene expression profiling identifies five transcriptional AML-MRC-related clusters**

564 **A)** Waterfall plot of aberrations in the AML-MRC-related clusters, including the percentage of samples
565 with the aberration. We did not plot enriched individual large chromosomal mishaps. The plot is combined
566 with heatmaps showing the expression of marker genes and cell type scores. The columns are samples,
567 which are split according to transcriptional clusters. MRC genes are *ASXL1*, *BCOR*, *EZH2*, *RUNX1*,
568 *SF3B1*, *SRSF2*, *STAG2*, *U2AF1*, or *ZRSR2*. Cytogenetic abnormalities are the ICC 2022 aberrations that
569 define AML-MRC with cytogenetic abnormalities. **B)** tSNE visualisation of patient samples, coloured
570 according to the FAB annotation. Only AML-MRC clusters samples are coloured; the rest
571 are in grey. **C)** Fraction of FAB annotations per cluster. **D)** Boxplots of cytolytic cell score per cluster. We
572 used a two-sided Wilcoxon test to test for statistical differences and Benjamini-Hochberg to adjust p-
573 values for multiple testing. Tests were performed only between the two *KMT2A*^T, the five *NPM1*^T and the
574 five *AML-MRC*^T clusters. FDR values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001. HSC = hematopoietic
575 stem cells, Prog. = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono.
576 = monocytes, cDC = conventional dendritic cells


577




578 **Figure 6: AML clusters exhibit cell type-independent differences in ex-vivo drug responses**




579 **A)** Heatmap coloured according to the median scaled area under the curve (AUC) of the ex-vivo drug
580 response per drug and cluster. On the left is the drug name, and on the right is the drug family. A green






581 colour indicates a lower median AUC for the drug for the samples in the cluster compared to the other
582 clusters, indicating a strong drug response. Red indicates a higher median AUC, meaning a weak drug
583 response. **B)** Boxplots showing ex-vivo drug responses for a selection of drugs. We performed
584 significance testing using a two-sided Wilcoxon test. FDR values: * < 0.05, ** < 0.01, *** < 0.05, **** <
585 0.001. **C)** Plots of the multivariate linear models with cluster membership and the six cell type scores as
586 independent variables and AUC as the dependent variable. On the x-axis, the coefficient of the variables
587 in the models is shown, and the y-axis shows the $-\log_{10}$ of the p-value for each variable. The shown p-
588 values are not corrected and are for visualisation to indicate variable importance in the multivariate model.
589 The corrected p-values of the cluster membership variable are shown in **Supplemental Table 3**. The red
590 line indicates a p-value of 0.05. **D)** Barplots of the top 40 drugs with highest corrected p-values for Kruskal-
591 Wallis tests between ex-vivo drug response and clusters or ICC 2022 diagnosis to test if there were
592 significant differences in the median AUCs. All p-values were corrected with Benjamini-Hochberg.

Figure 1



A**KMT2A fusions & NPM1 + trisomy 8/8q****Figure 2****B****C****FAB fractions**



**B** VAF of *NPM1* mutations**C** FAB annotations**D** FAB fractions**E** HLA I score**F** HLA II score